2015

New FDA guidelines jettison the 'traditional approach' to fulfilling the brief summary requirement and replaces it with what the FDA calls the 'Consumer Brief Summary.' This article summarizes the new guidelines and reviews the need for additional guidelines that specifically address the fair balance section of DTC print ads.

In a new survey, Pharma Marketing News asks your opinion about who should be the next FDA commissioner. The survey has been seeded with the candidates mentioned in this article. You can choose one of these or enter your own choice.

This article discusses real world examples of patient-centricity in pharmaceutical marketing and the need for more transparency in how pharmaceutical companies partner with patients online.

This article summarizes the results of the KOL Name Change Survey and discusses how to change the underlying process by which pharma companies choose KOLs.

Welcome to Volume 14, Issue #1 (JANUARY 2015) of Pharma Marketing News.

In this article, Pharmaguy presents the best images from Pharma Marketing Blog, which cover topics of importance in 2014: DTC and drug promotion spending, drug risks and adverse events, drug industry reputation, FDA and social media regulatory guidelines, mobile apps, and drug development costs.

Here's John Mack's list of 2015 resolutions for pharmaceutical marketers. Hopefully, at least one of these will be kept, although no one is making any promises.

The FDA approved a total of 41 new molecular entities (NMEs) and biologics (BLAs) in 201 4but sent out only a meager 10 advertising enforcement letters in 2014, the fewest ever.